325 related articles for article (PubMed ID: 26563355)
1. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
Sartore-Bianchi A; Ardini E; Bosotti R; Amatu A; Valtorta E; Somaschini A; Raddrizzani L; Palmeri L; Banfi P; Bonazzina E; Misale S; Marrapese G; Leone A; Alzani R; Luo D; Hornby Z; Lim J; Veronese S; Vanzulli A; Bardelli A; Martignoni M; Davite C; Galvani A; Isacchi A; Siena S
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563355
[TBL] [Abstract][Full Text] [Related]
2. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J
Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021
[TBL] [Abstract][Full Text] [Related]
3. N of 2 Responders with LMNA-NTRK1.
Lih CJ; Chen AP
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563357
[No Abstract] [Full Text] [Related]
4. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.
Créancier L; Vandenberghe I; Gomes B; Dejean C; Blanchet JC; Meilleroux J; Guimbaud R; Selves J; Kruczynski A
Cancer Lett; 2015 Aug; 365(1):107-11. PubMed ID: 26001971
[TBL] [Abstract][Full Text] [Related]
5. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
[TBL] [Abstract][Full Text] [Related]
6. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.
Park DY; Choi C; Shin E; Lee JH; Kwon CH; Jo HJ; Kim HR; Kim HS; Oh N; Lee JS; Park OK; Park E; Park J; Shin JY; Kim JI; Seo JS; Park HD; Park J
Oncotarget; 2016 Feb; 7(7):8399-412. PubMed ID: 26716414
[TBL] [Abstract][Full Text] [Related]
7. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Rolfo C; Ruiz R; Giovannetti E; Gil-Bazo I; Russo A; Passiglia F; Giallombardo M; Peeters M; Raez L
Expert Opin Investig Drugs; 2015; 24(11):1493-500. PubMed ID: 26457764
[TBL] [Abstract][Full Text] [Related]
8. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Ardini E; Menichincheri M; Banfi P; Bosotti R; De Ponti C; Pulci R; Ballinari D; Ciomei M; Texido G; Degrassi A; Avanzi N; Amboldi N; Saccardo MB; Casero D; Orsini P; Bandiera T; Mologni L; Anderson D; Wei G; Harris J; Vernier JM; Li G; Felder E; Donati D; Isacchi A; Pesenti E; Magnaghi P; Galvani A
Mol Cancer Ther; 2016 Apr; 15(4):628-39. PubMed ID: 26939704
[TBL] [Abstract][Full Text] [Related]
9. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Russo M; Misale S; Wei G; Siravegna G; Crisafulli G; Lazzari L; Corti G; Rospo G; Novara L; Mussolin B; Bartolini A; Cam N; Patel R; Yan S; Shoemaker R; Wild R; Di Nicolantonio F; Bianchi AS; Li G; Siena S; Bardelli A
Cancer Discov; 2016 Jan; 6(1):36-44. PubMed ID: 26546295
[TBL] [Abstract][Full Text] [Related]
10. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
[TBL] [Abstract][Full Text] [Related]
11. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
[TBL] [Abstract][Full Text] [Related]
12. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.
Amatu A; Somaschini A; Cerea G; Bosotti R; Valtorta E; Buonandi P; Marrapese G; Veronese S; Luo D; Hornby Z; Multani P; Murphy D; Shoemaker R; Lauricella C; Giannetta L; Maiolani M; Vanzulli A; Ardini E; Galvani A; Isacchi A; Sartore-Bianchi A; Siena S
Br J Cancer; 2015 Dec; 113(12):1730-4. PubMed ID: 26633560
[TBL] [Abstract][Full Text] [Related]
13. Foretinib Overcomes Entrectinib Resistance Associated with the
Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
[No Abstract] [Full Text] [Related]
14. Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib.
Wong V; Pavlick D; Brennan T; Yelensky R; Crawford J; Ross JS; Miller VA; Malicki D; Stephens PJ; Ali SM; Ahn H
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563356
[No Abstract] [Full Text] [Related]
15. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.
Chen Y; Steiner S; Hagedorn C; Kollar S; Pliego-Mendieta A; Haberecker M; Plock J; Britschgi C; Planas-Paz L; Pauli C
J Pathol; 2024 Jun; 263(2):257-269. PubMed ID: 38613194
[TBL] [Abstract][Full Text] [Related]
16. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.
Ukkola I; Nummela P; Kero M; Tammio H; Tuominen J; Kairisto V; Kallajoki M; Haglund C; Peltomäki P; Kytölä S; Ristimäki A
Virchows Arch; 2022 Apr; 480(4):807-817. PubMed ID: 35237889
[TBL] [Abstract][Full Text] [Related]
17. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
Ardini E; Bosotti R; Borgia AL; De Ponti C; Somaschini A; Cammarota R; Amboldi N; Raddrizzani L; Milani A; Magnaghi P; Ballinari D; Casero D; Gasparri F; Banfi P; Avanzi N; Saccardo MB; Alzani R; Bandiera T; Felder E; Donati D; Pesenti E; Sartore-Bianchi A; Gambacorta M; Pierotti MA; Siena S; Veronese S; Galvani A; Isacchi A
Mol Oncol; 2014 Dec; 8(8):1495-507. PubMed ID: 24962792
[TBL] [Abstract][Full Text] [Related]
18. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
Chong CR; Bahcall M; Capelletti M; Kosaka T; Ercan D; Sim T; Sholl LM; Nishino M; Johnson BE; Gray NS; Jänne PA
Clin Cancer Res; 2017 Jan; 23(1):204-213. PubMed ID: 27370605
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of a novel
Milione M; Ardini E; Christiansen J; Valtorta E; Veronese S; Bosotti R; Pellegrinelli A; Testi A; Pietrantonio F; Fucà G; Wei G; Murphy D; Siena S; Isacchi A; De Braud F
Oncotarget; 2017 Aug; 8(33):55353-55360. PubMed ID: 28903424
[TBL] [Abstract][Full Text] [Related]
20. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas.
Butti MG; Bongarzone I; Ferraresi G; Mondellini P; Borrello MG; Pierotti MA
Genomics; 1995 Jul; 28(1):15-24. PubMed ID: 7590742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
